- ImmunoGen (IMGN -1.2%) gives back yesterday's post-session gains and more after its FQ4 beat on a per share basis, reporting a narrower loss than the Street.
- Kadcyla sales off to a strong start in the U.S. for its first indication, with additional approvals expected.
- The company boosts guidance going forward, now expecting FY14 revenues of $66M - $70M, above the Street view of $49.9M.
Immunogen gives back early gains from an upbeat FQ4 report
Aug 2 2013, 13:16 ET